Literature DB >> 3316510

Preliminary clinical trial of immunotherapy for malignant glioma.

M Ingram1, C H Shelden, S Jacques, R G Skillen, W G Bradley, G B Techy, D B Freshwater, R M Abts, R W Rand.   

Abstract

An immunotherapy protocol based on intracranial implantation of stimulated, autologous lymphocytes into the tumor bed following surgical debulking of malignant glioma is described. Phase I clinical trials in human patients are now in progress. Preliminary data representing the first 39 patients treated are presented briefly.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3316510

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN： 0732-6580


  7 in total

1.  Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.

Authors:  C A Kruse; K O Lillehei; D H Mitchell; B Kleinschmidt-DeMasters; D Bellgrau
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

Review 3.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

4.  Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma.

Authors:  J Vaquero; R Martínez; S Oya; S Coca; L Barbolla; J Ramiro; F G Salazar
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

5.  Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.

Authors:  J Hanes; A Sills; Z Zhao; K W Suh; B Tyler; F DiMeco; D J Brat; M A Choti; K W Leong; D M Pardoll; H Brem
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

6.  Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

Authors:  A Mäenpää; S Junnikkala; J Hakulinen; T Timonen; S Meri
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 7.  Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

Authors:  P M Anderson; M A Sorenson
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.